Table 3

Sensitivity analysis for medication adherences according to age and numbers of medications

ARB-only group
(n=29 400)
CCB-only group
(n=58 401)
MPC group
(n=10 458)
SPC group
(n=18 418)
P value* MPR differences P value
Crude MPR meanAdjusted MPR mean§ (95% CI)Crude MPR meanAdjusted MPR mean§ (95% CI)Crude MPR meanAdjusted MPR mean§ (95% CI)Crude MPR meanAdjusted MPR mean§ (95% CI)
20–49 years (n=24 957)
 1–2 (n=6827)76.776.6 (75.6 to 77.6)75.874.7 (73.4 to 76.0)82.384.1 (80.2 to 88.0)83.484.8 (83.4 to 86.1)<0.010.70.78
 3–4 (n=11 768)78.278.5 (77.6 to 79.3)78.677.5 (76.8 to 78.3)85.686.7 (85.2 to 88.2)83.985.1 (84.1 to 86.1)<0.01−1.60.01
 5–6 (n=4595)78.178.6 (77.4 to 79.8)76.775.3 (74.0 to 76.6)82.283.9 (81.6 to 86.3)84.285.3 (83.5 to 87.0)<0.011.30.70
 7–9 (n=1360)79.479.3 (76.9 to 81.2)77.576.7 (74.1 to 79.4)76.778.6 (74.5 to 82.7)81.982.4 (79.0 to 85.8)<0.013.80.13
 ≥9 (n=407)68.767.1 (62.6 to 71.6)72.468.0 (63.1 to 73.0)73.281.4 (74.0 to 88.8)86.589.8 (82.4 to 97.1)<0.018.40.05
50–64 years (n=46 085)
 1–2 (n=7933)81.881.9 (81.0 to 82.9)81.481.0 (80.1 to 81.9)88.989.2 (85.6 to 92.9)88.589.3 (87.8 to 90.7)<0.010.10.45
 3–4 (n=20 396)82.583.0 (82.4 to 83.6)83.282.3 (81.9 to 82.8)88.389.5 (88.3 to 90.6)89.190.4 (89.6 to 91.2)<0.010.90.72
 5–6 (n=11 657)83.583.7 (83.0 to 84.4)83.883.2 (82.6 to 83.9)87.888.5 (87.3 to 89.8)90.391.1 (90.0 to 92.1)<0.012.5<0.01
 7–9 (n=4438)83.483.4 (82.2 to 84.5)82.580.4 (79.2 to 81.5)81.985.1 (83.1 to 87.1)89.992.3 (90.6 to 94.0)<0.017.2<0.01
 ≥9 (n=1661)79.278.8 (76.9 to 80.6)81.578.7 (76.7 to 80.8)78.283.4 (80.3 to 86.4)89.691.3 (88.3 to 94.3)<0.017.9<0.01
65–74 years (n=30 652)
 1–2 (n=3412)81.382.5 (80.6 to 84.4)81.180.3 (79.2 to 81.4)88.891.1 (85.5 to 96.8)88.991.0 (88.3 to 93.8)<0.01−0.10.94
 3–4 (n=11 308)83.583.9 (83.0 to 84.8)83.082.5 (81.9 to 83.1)88.789.2 (87.5 to 90.9)90.391.6 (90.3 to 92.9)<0.012.40.03
 5–6 (n=9267)83.183.1 (82.3 to 84.0)82.782.3 (81.6 to 83.0)88.088.3 (86.8 to 89.8)91.592.5 (91.2 to 93.8)<0.014.2<0.01
 7–9 (n=4562)81.381.7 (80.5 to 82.9)81.780.4 (79.3 to 81.5)85.487.4 (85.4 to 89.4)90.892.5 (90.7 to 94.4)<0.015.2<0.01
 ≥9 (n=2103)79.879.3 (77.5 to 81.1)79.177.1 (75.4 to 81.1)78.683.1 (79.9 to 86.2)90.292.5 (89.5 to 95.6)<0.019.5<0.01
≥75 years (n=14 983)
 1–2 (n=1351)80.681.0 (77.1 to 84.9)75.775.5 (73.8 to 77.3)82.483.1 (72.1 to 94.0)85.485.9 (80.3 to 91.5)<0.012.90.69
 3–4 (n=4916)79.280.4 (78.7 to 82.1)78.577.9 (77.0 to 78.9)85.285.6 (82.6 to 88.6)87.488.8 (86.3 to 91.2)<0.013.20.42
 5–6 (n=4586)79.880.5 (79.0 to 82.0)77.476.5 (75.4 to 77.6)83.485.2 (82.6 to 87.8)88.790.4 (87.9 to 92.8)<0.015.20.01
 7–9 (n=2711)79.379.6 (77.9 to 81.4)76.875.8 (74.3 to 77.2)83.185.3 (82.3 to 88.2)87.689.4 (86.4 to 92.3)<0.014.10.18
 ≥9 (n=1419)77.877.4 (75.1 to 79.7)75.574.9 (72.8 to 77.0)80.281.3 (77.1 to 85.4)85.788.6 (84.2 to 93.0)<0.017.40.06
  • Analyses were performed using ANCOVA.

  • *P value of crude MPR mean.

  • †MPR differences=adjusted MPR of SPC group – adjusted MPR of MPC group.

  • ‡P value of MPR differences.

  • §Adjusted for factors associated with the patient (age, sex), condition (comorbidity), therapy (drug costs, number of concurrent drugs, prescription period), the healthcare system (insurance coverage) and the social/economic status (income, residence).

  • ANCOVA, analysis of covariance; ARB, angiotensin II receptor blockers; CCB, calcium channel blockers; MPC,multiple-pill combination; MPR, medication possession ratio; SPC, single-pill combination.